מדינה: ארצות הברית
שפה: אנגלית
מקור: NLM (National Library of Medicine)
PROPRANOLOL HYDROCHLORIDE (UNII: F8A3652H1V) (PROPRANOLOL - UNII:9Y8NXQ24VQ), HYDROCHLOROTHIAZIDE (UNII: 0J48LPH2TH) (HYDROCHLOROTHIAZIDE - UNII:0J48LPH2TH)
Mylan Pharmaceuticals Inc.
PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE 40 mg
ORAL
PRESCRIPTION DRUG
Propranolol hydrochloride and hydrochlorothiazide tablets, USP are indicated in the management of hypertension. This fixed combination is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. Propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3) bronchial asthma; 4) congestive heart failure (see WARNINGS) unless the failure is secondary to a tachyarrhythmia treatable with propranolol. Hydrochlorothiazide is contraindicated in patients with anuria or hypersensitivity to this or other sulfonamide-derived drugs.
Propranolol Hydrochloride and Hydrochlorothiazide Tablets, USP are available in the following combinations: The 40 mg/25 mg tablets contain 40 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with MYLAN over 731 on one side of the tablet and scored on the other side. They are available as follows: NDC 0378-0731-01 bottles of 100 tablets The 80 mg/25 mg tablets contain 80 mg of propranolol hydrochloride, USP and 25 mg of hydrochlorothiazide, USP. Each white round scored tablet is debossed with MYLAN over 347 on one side of the tablet and scored on the other side. They are available as follows: NDC 0378-0347-01 bottles of 100 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture, freezing, and excessive heat. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Revised: 4/2020 PRAN/HCTZ:R21
Abbreviated New Drug Application
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE- PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLET MYLAN PHARMACEUTICALS INC. ---------- DESCRIPTION Propranolol hydrochloride and hydrochlorothiazide tablets, USP for oral administration combine two antihypertensive agents: propranolol hydrochloride, USP, a beta-adrenergic blocking agent, and hydrochlorothiazide, USP, a thiazide diuretic-antihypertensive. Propranolol hydrochloride and hydrochlorothiazide tablets, 40/25 contain 40 mg propranolol hydrochloride and 25 mg hydrochlorothiazide; propranolol hydrochloride and hydrochlorothiazide tablets, 80/25 contain 80 mg propranolol hydrochloride and 25 mg hydrochlorothiazide. Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent chemically described as 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol hydrochloride. Its structural formula is: Propranolol hydrochloride, USP is a stable, white, crystalline solid which is readily soluble in water and ethanol. Its molecular weight is 295.81. Hydrochlorothiazide, USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution; sparingly soluble in methanol; insoluble in ether, chloroform, benzene, and dilute mineral acids. Its chemical name is: 6-Chloro-3,4- dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its structural formula is: Propranolol hydrochloride and hydrochlorothiazide tablets, 40 mg/25 mg and 80 mg/25 mg are for oral administration and contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch (corn) and sodium lauryl sulfate. CLINICAL PHARMACOLOGY PROPRANOLOL HYDROCHLORIDE Propranolol hydrochloride is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor stimulating agents for available receptor sites. When acc קרא את המסמך השלם